Compass Therapeutics (CMPX) Amortization of Deferred Charges (2021 - 2026)

Compass Therapeutics has disclosed Amortization of Deferred Charges across 6 years of filings, most recently posting -$206000.0 for Q1 2026.

• Amortization of Deferred Charges for Q1 2026 came in at -$206000.0, down 892.31% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.9 million (down 52.52% YoY), and the FY2025 annual result was -$1.7 million, down 1.33% from the prior year.
• Amortization of Deferred Charges came in at -$206000.0 for Q1 2026 at Compass Therapeutics, up from -$1.2 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $110000.0 in Q2 2022 to a low of -$1.2 million in Q4 2025.
• The 5-year median for Amortization of Deferred Charges is -$375500.0 (2024), against an average of -$472312.5.
• Across the five-year window, Amortization of Deferred Charges sank 10283.33% in 2022 and jumped 106.91% in 2025, its largest moves.
• Compass Therapeutics' Amortization of Deferred Charges stood at -$611000.0 in 2022, then slumped by 32.9% to -$812000.0 in 2023, then surged by 66.75% to -$270000.0 in 2024, then slumped by 342.96% to -$1.2 million in 2025, then surged by 82.78% to -$206000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at -$206000.0 (Q1 2026), -$1.2 million (Q4 2025), and -$375000.0 (Q3 2025), per Business Quant data.